When does Viagra go generic?
Viagra’s brand-only period ends once the relevant patents for sildenafil (Viagra) expire and any remaining exclusivity runs out. That is what lets other manufacturers sell “generic sildenafil” (often marketed under different strengths and sometimes as sildenafil citrate tablets).
When did Viagra’s patent protection start ending?
The first major milestones for sildenafil generic entry happened as key patents around sildenafil expired in the U.S. and other markets, allowing FDA-approved generics to launch after approval and labeling work. Availability timing depends on the country and on which specific patent(s) a manufacturer is trying to work around or challenge.
What do people mean by “generic Viagra”?
In practice, “generic Viagra” usually means generic versions of sildenafil (the active ingredient in Viagra). These generics are typically approved by regulators as bioequivalent to Viagra and sold as sildenafil tablets, not as a new drug.
Can generics appear before all patents expire?
Sometimes. A company may file for approval using the original drug’s data (for example through an abbreviated pathway where permitted), but the FDA approval and marketing timing can be blocked or delayed by patent and exclusivity status. Once a listed patent is no longer preventing marketing—or is found not to apply—generics can launch even if other related patent families still exist.
What should you check if you’re trying to buy it?
Look for “sildenafil” on the label (generic) versus “sildenafil citrate” sold as a brand product, and check the country/market you’re in. Brand names and exact launch dates differ by region, and different strengths may come to market on different schedules.
What if you’re in a different country than the U.S.?
Generic timing varies by local patent law, patent listing practices, and exclusivity rules. If you tell me your country (and, if you want, the strength like 25 mg/50 mg/100 mg), I can narrow down the likely generic status there.
Sources
No sources were provided with the question.